// App-Quantinova.ai

: PATH-21. CLINICAL UTILITY OF DNA METHYLATION PROFILING FOR DIAGNOSIS OF CHALLENGING CENTRAL NERVOUS SYSTEM TUMORS: THE TORONTO EXPERIENCE

Researchers

Presenter

  • Shirin Karimi

Principal Investigators

  • Jeffrey Zuccato

  • Yasin Mamatjan

  • Sheila Mansouri

  • Suganth Suppiah

  • Farshad Nassiri

  • Phedias Diamandis

  • David Munoz

  • Kenneth Aldape

  • Gelareh Zadeh

Medical Centers

  • MacFeeters-Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Center, Toronto, ON, Canada

  • Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

  • Univ of Toronto, St Michael's Hosp, Toronto, ON, Canada

  • Laboratory of Tumor Immunology and Biology, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • Universtiy Health Network, Toronto, ON, Canada

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Oncology (ONC)

Disease

  • Medulloblastoma

  • Glioblastoma

  • Ependymoma

  • Cerebral metastases

  • Gliomas

Biomarkers

  • O-6-methylguanine DNA methyltransferase

  • DNA methylation

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved